Revolution Medicines publishes corporate deck outlining RAS(ON) inhibitor pipeline targeting RAS-driven cancers

• Revolution Medicines highlighted Phase 3 RASolute 302 data in previously treated metastatic pancreatic cancer for daraxonrasib versus IV chemotherapy.
• Overall survival hazard ratio 0.40, a 60% reduction in risk of death; median OS 13.2 months versus 6.7 months.
• U.S. FDA accepted the daraxonrasib NDA for review; EMA began a phased review of the marketing authorization application.
• Expanded access program supplied daraxonrasib for physicians on behalf of more than 2,000 patients across almost all 50 states.
• Pipeline update centered on oral RAS(ON) inhibitors, including zoldonrasib in combination regimens for KRAS G12D pancreatic cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.